106 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
, and market share growth; the potential benefits and advantages Immunocore’s products and product candidates, including KIMMTRAK and brenetafusp … ; statements regarding the benefits of the Company’s collaboration with Bristol-Meyers Squibb; the timing and sufficiency of clinical trial outcomes
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
-looking statements include, but are not limited to, statements about:
the therapeutic potential and expected clinical benefits of KIMMTRAK
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
casting a vote.
After considering the benefits and consequences of each alternative, our board of directors recommends that the advisory vote … and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
, but are not limited to, statements about:
the therapeutic potential and expected clinical benefits of KIMMTRAK;
the safety, efficacy and clinical progress of our … , but are not limited to, statements about:
the therapeutic potential and expected clinical benefits of KIMMTRAK;
the safety, efficacy and clinical
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
may abstain from casting a vote.
After considering the benefits and consequences of each alternative, our board of directors recommends … and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available
S-3ASR
pcvw94idge
20 Mar 24
Automatic shelf registration
8:51pm
8-K
EX-99.1
mkela
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
8-K
EX-99.2
t40tp48e vd3oo1hu5
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
EX-10.13
4nwnjtded x7wdl8
28 Feb 24
Annual report
7:33am
10-K
EX-97.1
8saq0jo
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
x05uod7voxvub6bo
28 Feb 24
Annual report
7:33am
10-K
EX-10.12
wrlg8ksr5oggjmn
28 Feb 24
Annual report
7:33am
10-K
pp4cj v8cvk
28 Feb 24
Annual report
7:33am
8-K
EX-4.1
eeiu1250jjz1
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
8-K
EX-99.2
y05z5zgnx
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.2
i8dzc 4fj
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.1
o6jltgjuzaew22
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.2
zt8j4j8nif
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
xbcs4daamj 1a8
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
gfch i4eo4wxjk89w
10 Aug 23
Current report (foreign)
8:28am